Presents
The Sherbrooke Molecular Imaging Centre (CIMS) is a world-class imaging centre covering preclinical and clinical imaging and spanning across basic research and the provision of imaging services. CIMS is located within the Research Centre of the Sherbrooke University Hospital (CRCHUS) in Canada. Recognized as a center of expertise in molecular imaging, the Sherbrooke Molecular Imaging Center (CIMS) operates PET imaging modalities, CT, MRI and optical fluorescence/bioluminescence imaging as tools for research and preclinical and clinical investigation.
Researchers at CIMS design and build new devices for PET and simultaneous PET/CT imaging, diffuse optical tomography, develop new biomarkers (PET radiotracers, magnetic contrast agents and optical sensors) and perform advanced image analysis and pharmacokinetic modeling to study living organisms non-invasively and to improve the diagnosis and treatment of diseases. CIMS is the first center of this scale in Canada. It includes preclinical and clinical imaging, and all resources for development, validation and production of new scanners and new biomarkers for three-dimensional imaging in animals and humans. It offers access to a platform of equipment at the cutting edge of technology within a single location in Sherbrooke, Quebec, for both preclinical and clinical research applications. The basic research projects carried out through preclinical studies on animal models are translated to clinical and clinical research and applications in the field of nuclear medicine, radiation oncology, neuroscience and radiobiology.
This is especially the case for projects involving multimodality imaging with applications in oncology, cardiology, neurology and metabolism (e.g., diabetes). For preclinical research, CIMS is the best equipped and most active multimodality imaging center in Canada, offering the best one-stop shop for preclinical imaging studies. Clinically, CIMS, since its opening in 1998, has become the most active PET centre in Canada (5,000 scans per year), and among the most active in North America, offering a broad population base for recruitment of patients in clinical studies. CIMS also has key partnerships with Charles River Laboratories and Imeka. The partnerships allows CIMS to offer a complete range of services. Watch to learn more: www.usherbrooke.ca/dep-medecine-nucleaire-radiobiologie
US & Canadian Academy of Pathology (USCAP)
